Table 1.
Participant demographics
| Full dataset | A-subset | |
|---|---|---|
| Number of specimens | 58 | 35 |
| Sex (% male) | 60.3 | 57.1 |
| Age (years) Median (range) | 75.0 (44–97) years | 73.0 (44–93) years |
| Mean ± SD | 74.7 ± 11.3 years | 72.0 ± 10.7 years |
| MTL Tau score | ||
| Mean ± SD (range) | 1.64 ± 0.93 (0–3) | 1.34 ± 0.96 (0–3) |
| % score > 0 (N) | 96.6% (56) | 94.3% (33) |
| MTL TDP-43 score | ||
| Mean ± SD (range) | 0.47 ± 0.91 (0–3) | 0.52 ± 0.99 (0–3) |
| % score > 0 (N) | 27.6% (16) | 25.7% (9) |
| MTL amyloid-β scores | ||
| Mean ± SD (range) | 0.92 ± 0.99 (0–3) | 0.31 ± 0.59 (0–3) |
| % score > 0 (N) | 63.8% (37) | 40.0% (14) |
| MTL α-synuclein score | ||
| Mean ± SD (range) | 0.21 ± 0.54 (0–2.33) | 0.08 ± 0.30 (0–1.67) |
| % score > 0 (N) | 17.2% (10) | 8.6% (3) |
| Primary neuropathological diagnosis | ||
| None/limited pathologya | 20.7% (8) | 31.4% (7) |
| Intermediate-high ADNC | 25.9% (15) | 0% (0) |
| CBD | 5.2% (3) | 8.6% (3) |
| FTLD-TDP | 13.8% (8) | 20.0% (7) |
| LBD | 8.6% (5) | 2.9% (1) |
| Otherb | 13.8% (7) | 17.1% (6) |
| PART | 8.6% (5) | 14.3% (5) |
| Pick’s disease | 5.2% (3) | 8.6% (3) |
| PSP | 6.9% (4) | 8.6% (3) |
| Two or more neuropathological diagnoses | 70.7% (41) | 65.7% (23) |
| A score | ||
| 0 | 25.9% (15) | 42.9% (15) |
| 1 | 34.5% (20) | 57.1% (20) |
| 2 | 8.6% (5) | 0.0% (0) |
| 3 | 31.0% (18) | 0.0% (0) |
| B score | ||
| 0 | 22.4% (13) | 37.1% (13) |
| 1 | 29.0% (18) | 42.9% (15) |
| 2 | 20.0% (11) | 14.3% (5) |
| 3 | 21.0% (13) | 0.0% (0) |
| Missing | 11.3% (3)b | 5.7% (2)b |
| C score | ||
| 0 | 55.% (32) | 82.9 (29) |
| 1 | 17.2% (10) | 17.1% (6) |
| 2 | 3.4% (2) | 0.0% (0) |
| 3 | 24.1% (14) | 0.0% (0) |
The MTL pathology scores shown in the table are the averages of the semi-quantitative ratings in the entorhinal cortex, cornu ammonis 1 and dentate gyrus from the hemisphere contralateral to the MRI scan
MTL medial temporal lobe, TDP TAR DNA-binding protein, ADNC Alzheimer’s disease neuropathological change, CBD corticobasal degeneration, FTLD frontotemporal lobar degeneration, LBD Lewy body disease, PART primary age-related tauopathy, PSP progressive supranuclear palsy. aAlso includes patients with low ADNC. bB score was difficult to establish for some cases because they had primary tauopathies. b”Other” includes the following primary neuropathological diagnoses: Amyotrophic Lateral Sclerosis (n = 1); Argyrophylic Grain Disease (n = 2); cerebrovascular disease (n = 1); multiple system atrophy (n = 1); other (n = 1); tauopathy unclassifiable (n = 1)